Regeneron Pharmaceuticals D
D
REGN
588.31
USD
-8.34
(-1.40%)
مفتوح الان
حجم التداول
12,211
الربح لكل سهم
35
العائد الربحي
0.29
P/E
15
حجم السوق
63,517,181,540
الأخبار المقالات
العنوان: Regeneron Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).